LOCAL FAS/APO-1 (CD95) LIGAND-MEDIATED TUMOR-CELL KILLING IN-VIVO

被引:196
作者
RENSINGEHL, A
FREI, K
FLURY, R
MATIBA, B
MARIANI, SM
WELLER, M
AEBISCHER, P
KRAMMER, PH
FONTANA, A
机构
[1] UNIV ZURICH HOSP,DEPT NEUROSURG,CH-8091 ZURICH,SWITZERLAND
[2] UNIV ZURICH HOSP,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND
[3] GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,DIV IMMUNOGENET,W-6900 HEIDELBERG,GERMANY
[4] UNIV TUBINGEN HOSP,DEPT NEUROL,TUBINGEN,GERMANY
[5] UNIV HOSP CTR LAUSANNE,DIV RES,LAUSANNE,SWITZERLAND
关键词
FAS/APO-1; LIGAND; APOPTOSIS; TUMOR; CD95;
D O I
10.1002/eji.1830250821
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fas/APO-1 (CD95) is a cell surface receptor which mediates apoptosis when ligated by specific antibodies or by its recently cloned natural ligand, FasL. We have studied the cytotoxic potential of Fast in vivo using Fas/APO-1-expressing Yac-1 cells as targets. Supernatant harvested from Neuro-2a cells transfected with the murine Fast cDNA contains Fast and transduces a potent apoptotic signal to Yac-l cells in vitro. Specificity of Fast-mediated cytotoxicity was con firmed by competition assays using soluble Fas or anti-Fas/APO-1 F(ab')(2) fragments which specifically interfere with FasL-Fas/APO-1 interactions. Intraperitoneal injection of Fast-containing supernatant efficiently killed Yac-l target cells which had been implanted in capsules into the peritoneal cavity of mice. Analysis of the target cells revealed DNA fragmentation and nuclear changes typical of apoptosis. As previously shown, intraperitoneal injection of anti-Fas/APO-1 antibodies caused liver failure (Ogasawara, J., Watanabe, F.R., Adachi, M., Matsuzawa, A., Kasugai, T, Kitamura, Y., Itoh, N., Suda, T. and Nagata, S., Nature 1993. 364: 806) and was observed at doses which did not reduce Yac-l cell viability. In contrast, Fast did not induce histopathology in the liver when applied intraperitoneally at doses cytotoxic for Yac-l cells. However, intravenous administration of Fast induced lethal liver hemorrhages and hepatocyte apoptosis. Thus, locally applied Fast kills tumor cells very efficiently without systemic toxicity and may therefore represent a candidate for local tumor treatment.
引用
收藏
页码:2253 / 2258
页数:6
相关论文
共 37 条
[1]  
Kerr J.F.R., Wyllie A.H., Currie A.R., Br. J. Cancer, 26, (1972)
[2]  
Wyllie A.H., Kerr J.F.R., Currie A.R., Int. Rev. Cytol., 68, (1980)
[3]  
Cohen J.J., Immunol. Today, 14, (1993)
[4]  
Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S., Cell, 66, (1991)
[5]  
Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li W.M., Richards S., Dhein J., Trauth B.C., Ponstingl H., Krammer P.H., J. Biol. Chem., 267, (1992)
[6]  
Suda T., Takahashi T., Golstein P., Nagata S., Cell, 75, (1993)
[7]  
Rouvier E., Luciani M.F., Golstein P., J. Exp. Med., 177, (1993)
[8]  
Kagi D., Vignaux F., Ledermann B.B., Depraetere V., Nagata S., Hengartner H., Golstein P., Science, 265, (1994)
[9]  
Lowin B., Hahne M., Mattmann C., Tschopp J., Nature, 370, (1994)
[10]  
Vignaux F., Golstein P., Eur. J. Immunol., 24, (1994)